Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 11/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.39 |
| ▸ | DPP4 | P27487 | 4/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6100308 | 0.89 | PREP (0.52) | PREPITGB3ITGA2BTSHRDPP7 | |
| SCHEMBL6872889 | 0.88 | PREP (0.55) | PREPITGB3ITGA2BTSHRDPP7 | |
| SCHEMBL5351068 | 0.85 | PREP (0.57) | PREPITGB3ITGA2BTSHRDPP7 | |
| SCHEMBL27586353 | 0.85 | PREP (0.57) | PREPITGB3ITGA2BTSHRDPP7 | |
| SCHEMBL4913602 | 0.85 | DPP7 (0.54) | PREPITGB3ITGA2BTSHRDPP7 | |
| SCHEMBL4906556 | 0.84 | ITGB3 (0.56) | PREPITGB3ITGA2BTSHRDPP7 | |
| SCHEMBL10074274 | 0.84 | ITGB3 (0.56) | PREPITGB3ITGA2BTSHRDPP7 | |
| SCHEMBL4913612 | 0.83 | PREP (0.50) | PREPITGB3ITGA2BTSHRDPP7 | |
| SCHEMBL23326163 | 0.81 | ITGB3 (0.48) | ITGB3ITGA2BTSHR | |
| SCHEMBL23326162 | 0.81 | ITGB3 (0.48) | ITGB3ITGA2BTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144886-B2 | Dipeptidyl peptidase IV (DP-IV) inhibitors as anti-diabetic agents | FERRING B.V. (NL) | 2006-12-05 | — | — | US | disclosed |
| US-20050004205-A1 | Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents | FERRING B.V. (NL) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004205-A1 | Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents | DPP4, DPP8, DPP3 | PREP 30/4885ITGB3 2464/4885ITGA2B 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.